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doi:10.1016/j.jfma.2012.01.014Background/Purpose: Erosive oral lichen planus (EOLP) is a T-cell-mediated inflammatory
disease that is refractory to treat. This study tested whether local injection of triamcinolone
acetonide plus oral administration of low- or medium-dose prednisolone could hasten the heal-
ing of EOLP lesions.
Methods: In this study, 50 EOLP patients were treated with local injection of Kenacort A (40 mg
triamcinolone acetonide once weekly for 3 and 2 weeks for 30 major and 20 minor EOLP
patients, respectively) plus oral administration of prednisolone (25e30 mg and 15e20 mg of
prednisolone once daily for 2 weeks for 30 major and 20 minor EOLP patients, respectively).
The oral administration of prednisolone was tapered to 5 mg per day and stopped in 7 days.
Then, the patients were treated with topical Dexaltin (0.1% dexamethasone, once or twice
per daily) and oral administration of vitamin Bc (one capsule twice daily) thereafter.
Results: After 3-week treatments, the 30 major EOLP patients showed complete response (lack
of detectable erosive or ulcerative lesion with absence or regression of reticular or papular
OLP) in 27 cases (90%) and partial response (reduction of erosive or ulcerative lesion by at least
30% in diameter with regression of reticular or papular OLP) in cases (10%); and 20 minor EOLP
patients demonstrated complete response in 18 cases (90%) and partial response in two cases
(10%). However, all the 45 complete response major or minor EOLP patients showed recurrence
of erosive or ulcerative lesion after 3e24 (mean 12) months of follow-up.
Conclusion: Prompt and complete healing of the EOLP lesions could be achieved in a relative
short period of time after treatment with our protocol. Although complete response EOLPof Dentistry, National Taiwan University Hospital, 1 Chang-Te Street, Taipei 10048, Taiwan.
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Treatment of erosive oral lichen planus 217lesions recurred after a follow-up period of 3e24 months, patients did have an average remis-
sion period of 12 months after treatment with our protocol.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Oral lichen planus (OLP) is a chronic inflammatory oral
mucosal disease. Both antigen-specific and nonspecific
mechanisms are involved in the pathogenesis of OLP.
Antigen-specific mechanisms include antigen presentation
by basal keratinocytes and antigen-specific keratinocyte
killing by CD8þ cytotoxic T lymphocytes. Nonspecific
mechanisms include mast cell degranulation and matrix
metalloproteinase activation in OLP lesions.1,2 Through
mast cell/T-cell interactions in OLP lesions, mast cell-
released cytokines, chemokines and matrix metal-
loproteinases can promote T-cell activation, migration,
proliferation and differentiation.3 OLP is histologically
characterized by liquefaction degeneration of basal
epithelial cells and an intraepithelial and subepithelial
infiltrate of CD8þ cells in the superficial lamina propria.
CD4þ cells are observed mainly in the deep lamina propria.4
An increase in histocompatibility leukocyte antigen (HLA)-
DR-positive CD3þ cells in both the local lesional tissues and
peripheral lymphocytes also indicates T-cell activation in
OLP.5,6 The above findings suggest that OLP is a T-cell-
mediated inflammatory disease.
Clinically, patients with the reticular, papular or plaque
type of OLP usually have minor or no symptoms, but
patients with erosive OLP (EOLP) often have significant
symptoms of pain and a burning sensation at the oral
mucosa. Therefore, the most important aim of EOLP
treatment is to promote the healing of erosive or ulcerative
oral mucosal lesions. This study tested whether local
injection of 40 mg triamcinolone acetonide once weekly for
2e3 weeks plus oral administration of 15e30 mg predniso-
lone once daily for 2 weeks could hasten the healing of
EOLP lesions and allow the OLP patients to obtain a rela-
tively long period of lesion remission.Materials and methods
Subjects
The study group consisted of 50 EOLP patients (seven men
and 43 women, age range 29e78 years, mean 54.8 years)
without LP of other mucosal or skin surfaces. All the
patients were seen consecutively, diagnosed, and treated
in the Department of Oral Diagnosis of National Taiwan
University Hospital from July 2005 to June 2008. OLP
patients with areca quid chewing habit, hypertension, and
autoimmune diseases such as systemic lupus eryth-
ematosus, rheumatoid arthritis, Sjo¨gren’s syndrome,
pemphigus vulgaris, and cicatricial pemphigoid were
excluded. In addition, none of the patients had taken any
prescription medication for at least 3 months before
entering the study. Patients were selected according to thefollowing criteria: (1) a typical clinical presentation of
radiating grayish-white Wickham striae or papules
combined with erosion or ulceration on the bilateral
posterior buccal or vestibular mucosa; and (2) biopsy
specimens characteristic of OLP, that is, hyperkeratosis or
parakeratosis, a slightly acanthotic epithelium with lique-
faction degeneration of the basal epithelial cells,
a pronounced band-like lymphocytic infiltrate in the lamina
propria, and the absence of epithelial dysplasia. The EOLP
was further divided into the major (30 patients with erosive
or ulcerative lesions  1 cm in diameter) and minor types
(20 patients with erosive or ulcerative lesions < 1 cm in
diameter) according to criteria described previously.7
After pathological diagnosis was confirmed, the 50 EOLP
patients were treated with a local injection of 40 mg
Kenacort A (triamcinolone acetonide) that was dissolved in
2 mL injection water and injected into the submucosa of
the erosive or ulcerative OLP lesions at the bilateral
posterior buccal or vestibular mucosa (1 mL for each side of
lesion). The local injection was performed once weekly for
2 (for minor EOLP patients) or 3 weeks (for major EOLP
patients). In addition, oral administration of 15e20 mg of
prednisolone (for minor EOLP patients) or 25e30 mg of
prednisolone (for major EOLP patients) once daily was
given to each patient for 2 weeks. The oral administration
of prednisolone was tapered to 5 mg per day and stopped in
7 days. Then, the patients were treated with topical Dex-
altin (0.1% dexamethasone, once or twice daily) and oral
vitamin Bc (one capsule twice daily) thereafter. The
patients were examined once a week for 4 weeks and then
once a month thereafter. Clinical photographs were taken
at each patient visit for evaluation of lesion progression or
regression. Lesion response was evaluated with special
regard to the erosive or ulcerative lesions and character-
ized as follows: complete response, lack of detectable
erosive or ulcerative lesion with absence or regression of
reticular or papular OLP confirmed by clinical evaluation;
partial response, reduction of erosive or ulcerative lesion
by at least 30% in diameter with regression of reticular or
papular OLP; and no response, reduction of erosive or
ulcerative lesion by less than 30% in diameter with regres-
sion of reticular or papular OLP. All lesion responses were
evaluated at the completion of the 3-week treatment. The
duration of recurrence was measured from the end of the 3-
week treatment to the time of recurrence. This study was
reviewed and approved by the Institutional Review Board at
the National Taiwan University Hospital.
Results
In this study, 50 EOLP patients were treated with local
injection of Kenacort A (40 mg triamcinolone acetonide
once weekly for 3 and 2 weeks for 30 major and 20 minor
EOLP patients, respectively) plus oral prednisolone
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weeks for 30 major and 20 minor EOLP patients, respec-
tively). After the 3-week treatments, the 30 major EOLP
patients showed complete response in 27 cases (90%)
(Fig. 1) and partial response in three cases (10%); and the
20 minor EOLP patients demonstrated complete response in
18 cases (90%) (Fig. 2) and partial response in two cases
(10%) (Table 1). The EOLP patients were then treated with
topical Dexaltin once or twice daily and oral vitamin Bc
(one capsule twice daily) 3 weeks later. All the 27 complete
response major EOLP patients showed recurrence of
erosive or ulcerative lesion after 3e24 (mean 12 5)
months of follow-up. In addition, all the 18 complete
response minor EOLP patients demonstrated recurrence of
erosive or ulcerative lesion after 3e24 (mean 12 6)
months of follow-up (Table 2). The recurrence EOLP
patients were treated with the same protocol (local
injection plus oral administration of corticosteroid) as
before and the majority of the patients could achieveFigure 1 Clinical photographs of a patient with major-type eros
mucosa. (A and B) Before treatment. (C and D) After one round of
plus oral administration of 25 mg prednisolone once daily for 1 we
rounds of local injection of 40 mg triamcinolone acetonide once we
for 2 weeks, showing complete healing of the ulcerative lesion witcomplete response after receiving the same treatment
modality (data not shown).Discussion
This study found that 90% of erosive or ulcerative OLP lesions
could show complete regression after 2e3 weeks of treat-
ment with local injection of triamcinolone acetonide plus
oral administration of low- or medium-dose prednisolone for
2 weeks. This suggests that a prompt and complete healing
of the erosive or ulcerative EOLP lesions can be achieved in
a relative short period of 2e3 weeks after treatment with
our protocol. However, the EOLP lesion did recur 3e24
(mean 12) months after complete response of the lesion had
been achieved. By asking the patients, the recurrence of the
EOLP lesions was usually elicited by episodes such as
insomnia for a few days, a common cold, a great emotional
disturbance, or a sudden disaster within the family.ive oral lichen planus (EOLP) on the bilateral posterior buccal
local injection of 40 mg triamcinolone acetonide once weekly
ek, showing partial response of the lesion. (E and F) After two
ekly plus oral administration of 25 mg prednisolone once daily
h residual reticular-type oral lichen planus.
Figure 2 Clinical photographs of a patient with minor-type erosive oral lichen planus (EOLP) on the bilateral posterior buccal
mucosa. (A and B) Before treatment. (C and D) After two rounds of local injection of 40 mg triamcinolone acetonide once weekly
plus oral administration of 15 mg prednisolone once daily for 2 weeks, showing nearly complete regression of the lesion.
Table 2 Recurrence of erosive oral lichen planus (EOLP)
lesions in 27 major EOLP and 18 minor EOLP patients with
complete response after 3-week treatments of local injec-
tion and oral administration of corticosteroid.
Duration (mo) Number of patients
Total
(nZ 45)
Major EOLP
(nZ 27)
Minor EOLP
(nZ 18)
3 2 1 1
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tory and anti-immune effects. Glucocorticoids suppress the
inflammatory response by inhibiting synthesis of the two
main inflammatory products, prostaglandins and leukotri-
enes. Glucocorticoids can inhibit prostaglandin synthesis
at the level of both phospholipase A2 and cyclo-
oxygenaseisomerase.8 Furthermore, glucocorticoids are
able to prevent the transcription of pro-inflammatory
genes, including interleukins(IL) IL-1B, IL-4, IL-5, and IL-8,
chemokines, cytokines, granulocyte-macrophage colony-
stimulating factor, and tumor necrosis factor-a genes.9
Glucocorticoids also suppress cell-mediated immunity.
They act by inhibiting genes that code for the cytokines IL-
1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and interferon-g, the most
important of which is IL-2 which is a potent T cell growth
factor. Smaller cytokine production in turn reducesT-cell-
proliferation.10 As stated before, OLP is a T-cell-mediated
chronic inflammatory oral mucosal disease and corticoste-
roids have both anti-inflammatory and anti-T cell-mediated
immune functions. Therefore, it is easy to understand whyTable 1 Lesion response in 30 patients with major erosive
oral lichen planus (EOLP) and 20 patients with minor EOLP
after 3-week treatments of local injection and oral admin-
istration of corticosteroid.
Number of patients
Total Complete
response
Partial
response
EOLP patients 50 45 5
Major type 30 27 3
Minor type 20 18 2local injection and systemic administration of corticoste-
roid can result in the accelerated healing of erosive and
ulcerative oral lesions in EOLP patients.
Conventional EOLP therapies are primarily aimed at
healing erosive and ulcerative EOLP lesion and relieving
oral mucosal pain and burning sensation. The available
treatments for EOLP consist of topical and systemic
corticosteroids, retinoids, calcineurin inhibitors such as
cyclosporine, tacrolimus and pimecrolimus, as well as4 2 1 1
6 3 2 1
8 4 2 2
9 6 4 2
10 6 4 2
12 5 3 2
14 1 0 1
15 5 3 2
16 1 1 0
18 4 2 2
20 1 1 0
21 3 2 1
24 2 1 1
220 R.-C. Kuo et al.extracorporeal photochemotherapy. Among these treat-
ment modalities, topical corticosteroids have been used as
the first-line drugs, while systemic corticosteroids are
usually reserved for widespread EOLP or acute exacerba-
tion.1,2 Topical application of corticosteroids could not
maintain a high local corticosteroid concentration for
a period long enough to promote the healing of erosive and
ulcerative oral lesion. Furthermore, in order to obtain
a high local corticosteroid concentration by oral adminis-
tration of corticosteroid, a large dose of corticosteroid
would need to be given to the patients. Therefore we used
local injection of triamcinolone acetonide to achieve a high
and relatively long-lasting local corticosteroid level in
a short period of time. We suggest that our EOLP treatment
protocol not only hastens the healing of erosive and
ulcerative oral lesion in a short period of 2e3 weeks, but
also frees the EOLP patients from long-term oral mucosal
discomfort and gives a relatively long symptom-free
remission period.
EOLP is a persistent, chronic inflammatory disease that
frequently causes oral mucosal discomfort and is resistant
to treatment. In this study, we used a local injection and
oral administration of corticosteroid treatment protocol to
treat 50 EOLP patients. We found that our treatment
protocol could accelerate the healing of ELOP lesion and
obtain a 90% complete response rate. Although complete
response EOLP lesions recurred after a follow-up period of
3e24 months, EOLP patients did have an average remission
period of 12 months after treatment with our protocol. In
addition, the recurrence EOLP lesion could acquire the
same clinical outcome as before when treated with the
same protocol. Therefore, we suggest that our newly
developed local injection and oral administration ofcorticosteroid treatment protocol may be a promising
treatment modality for EOLP in the future.
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